Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06470828 · ClinicalTrials.gov registry record · Phase 3
A Study of TAK-861 for the Treatment of Narcolepsy Type 1
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 168
- Enrollment target
NCT06470828 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 168 participants.
The verdict
NCT06470828, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 168 participants
- Enrollment target
Study Summary
The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms, and daily life functions; and to learn about the safety of TAK-861.
Interventions
- DRUG Placebo
- DRUG TAK-861
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2025-06-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06470828
The ClinicalTrials.gov registry entry for NCT06470828 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06470828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06470828 about?
NCT06470828 is a clinical study titled "A Study of TAK-861 for the Treatment of Narcolepsy Type 1". The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle w...
What is the current status of trial NCT06470828?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 168 participants. The study started on 2024-07-02. Estimated completion is 2025-06-03.
What interventions are being tested in trial NCT06470828?
The interventions under investigation include: Placebo (DRUG), TAK-861 (DRUG).
Who is sponsoring clinical trial NCT06470828?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.